- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04744857
Safety and Efficacy of TaurusOne® Transcatheter Aortic Valve Replacement System With Retrievable Delivery Catheter System
February 18, 2021 updated by: Peijia Medical Technology (Suzhou) Co., Ltd.
A Prospective,Multicenter, Single-arm Clinical Trial to Evaluate Safety and Efficacy of TaurusOne® Transcatheter Aortic Valve Replacement System With Retrievable Delivery Catheter System
The TaurusOne® transcatheter aortic valve system with retrievable delivery catheter system is evaluated the safety and effectiveness for the delivery of artificial aortic valve in a prospective, multicenter, single-arm clinical trial.
Study Overview
Status
Completed
Conditions
Detailed Description
The TaurusOne® transcatheter aortic valve system with retrievable delivery catheter system is evaluated the safety and effectiveness for the delivery of artificial aortic valve in a prospective, multicenter, single-arm clinical trial.
According to the inclusion and exclusion criteria, sixty patients are planed been enrolled and implanted with TaurusOne® .Patients are seen at pre and post procedure, discharge, 30 days.
The main follow-up included clinical symptoms and signs, cardiac ultrasound, CT, etc.
The outcome included immediate device success, procedure success, And the major cardiovascular and cerebrovascular adverse events (MACCE, including mortality, stroke, myocardial infarction, reoperation, arrhythmia, conduction block).
Study Type
Interventional
Enrollment (Actual)
85
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215025
- Peiga Medical Technology (Suzhou) Co., Ltd
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
70 years and older (OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients who are willing to participate and sign the informed consent and can cooperate with the whole trial process;
- Age ≥70 years old;
- Patients with severe calcified aortic stenosis confirmed by echocardiography (trans-aortic valve flow velocity ≥ 4.0m /s, or trans-active valvular pressure difference ≥40mmHg (1mmHg=0.133kPa), or aortic valve orientation area < 0.8cm2, or effective aortic valve orifice the product index is < 0.5cm2/m2);
- Appear obvious symptoms caused by aortic stenosis, NYHA class Ⅱ or higher;
- The cardiac team (at least two specialists in cardiovascular surgery) assessed the patient as unsuitable for routine surgery ;
- The life expectancy of the patient after implantation of the prosthetic valve was evaluated by the cardiac team (at least two specialists in cardiovascular surgery) as more than one year;
- Patients with aortic ring diameter ≥18mm and ≤29mm (cardiac CT measurement);
- The diameter of the ascending aorta of the patient was < 50mm.
Exclusion Criteria:
- Patients with bacteremia or toxemia;
- previous history or active endocarditis;
- Acute myocardial infarction (Q-wave MI, or non-Q-wave MI with increased creatine kinase isoenzyme and/or troponin T) within 30 days;
- Echocardiography found any intracardiac mass, left ventricle or atrial thrombosis, vegetations;
- Symptomatic atrial fibrillation that cannot be improved by medication;
- Familial hypertrophic cardiomyopathy;
- Mitral valve and tricuspid valve insufficiency (reflux Ⅱ level above);
- Prior aortic valve grafts (mechanical or biological valve stents);
- Known allergy to contrast agent, aspirin, heparin, ticlopidine, nickel-titanium memory alloy, or bovine products;
- Known to be contraindication or allergic to all anticoagulant regimens, or unable to use anticoagulant during the test;
- Other serious diseases that may reduce life expectancy to less than 12 months (e.g. clinically recurrent or metastatic cancer, congestive heart failure, etc.)
- Current drug abuse problem (e.g., alcohol, cocaine, heroin, etc.); Plan to undergo surgery that may cause nonadherence to protocol or confusion in data interpretation.
- Cerebrovascular accident (CVA) in the past 6 months;
- Patients with common or internal carotid or vertebral artery stenosis (> 70%);
- WBC count < 3×109/L, platelet count < 50×109/ L;
- Hemoglobin < 90g/L;
- Patients with severe coagulation dysfunction;
- Severe left ventricular dysfunction, left ventricular ejection fraction < 20%;
- Abdominal or thoracic aortic aneurysm;
- Hepatic encephalopathy or acute active hepatitis;
- Receiving dialysis or a baseline creatinine level of > 3.0 mg/dL (266μmol/L);
- Have bleeding tendency or history of coagulation disease or refuse blood transfusion;
- Have active gastric ulcer or active gastrointestinal (GI) bleeding;
- Suffer from neurological diseases that seriously affect the ability to move or live in daily life;
- People with mental illness or mental disorder who cannot express themselves normally;
- Need emergency surgery for any reason;
- Screening participants who had participated in other drug or medical device clinical trials within the previous 3 months;
- Other conditions considered by the investigator to be inappropriate for participation in this clinical trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: A single set of test
The experimental apparatus consisted of artificial aortic valve, transporter and grip-loading system.
|
Using the grip-loading system, the artificial aortic valve was squeezed and loaded into the sheath of the transporter through the vascular approach.The artificial aortic valve is delivered and positioned at the correct anatomical position for release.
For example, the artificial main valve is displayed after partial release If the aortic valve is not in the correct anatomical position, the artificial aortic valve can be recovered and placed into the sheath tube of the transporter for re-positioning and release.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite event rate at 30 days
Time Frame: 30 days after procedure
|
Patient-oriented composite event including all-cause death,severe stroke,myocardial infarction, permanent pacemaker implantation,surgical reoperation and valve-in-valve.
|
30 days after procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Device success rate (immediately after procedure)
Time Frame: Immediately after procedure
|
Device success is defined as
|
Immediately after procedure
|
Procedure success rate
Time Frame: 72 hours after procedure/prior to discharge
|
Procedure success is defined as the artificial aortic valve successfully implanted in the correct anatomical position 72h after surgery or before discharge without severe artificial aortic valve regurgitation or perivalvular leakage.
|
72 hours after procedure/prior to discharge
|
Cardiac function improvement
Time Frame: 30 days after procedure
|
Cardiac function improvement is accessed by NYHA cardiac function classification increases from baseline to 30 days.
|
30 days after procedure
|
Quality of life of patients
Time Frame: 30 days after procedure
|
Quality of Life of patients accessed by EuroQol-5 Dimensions (EQ-5D) Questionnaire.
The higher scores mean a worse health state.
Recording changes from baseline to 30 days.
|
30 days after procedure
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Product performance evaluation
Time Frame: Immediately after procedure
|
Product Performance includes grip loading, emptying , delivery, release, retrace, development and retrieval performance of delivery catheter system.
Every item measured by:1=good 2=average 3=poor.
|
Immediately after procedure
|
operative complication
Time Frame: Immediately after procedure
|
The rate of operative complication
|
Immediately after procedure
|
The incidence of major adverse cardiovascular and cerebrovascular events during the trial(MACCEs)
Time Frame: 30 days after procedure
|
Incidence of MACCEs (including mortality, stroke, myocardial infarction, and so on surgery, arrhythmias, conduction blocks) during the trial.
|
30 days after procedure
|
Incidence of major adverse valvular events (MAVREs) during the trial
Time Frame: 30 days after procedure
|
Incidence of MAVREs (including artificial aortic valve-related death, permanent cardiac pacemaker or defibrillator implantation, artificial aortic valve embolism or thrombosis, artificial aortic valve loss of function) during the trial.
|
30 days after procedure
|
hemorrhage
Time Frame: 30 days after procedure
|
Rate of patients with hemorrhage during the trial.
|
30 days after procedure
|
acute kidney injury
Time Frame: 30 days after procedure
|
Rate of patients with acute kidney injury during the trial.
|
30 days after procedure
|
Other TAVI related complications
Time Frame: 30 days after procedure
|
Rate of patients with Other TAVI related complications during the trial.
Other TAVI related complications include conversion to surgery, accidental cardiopulmonary mechanical assistance, coronary occlusion, ventricular septal perforation, mitral valve damage or loss of function, pericardial tamponade, endocarditis, valvular thrombosis, valvular ectopic (displacement, embolization, erroneous release), etc.
|
30 days after procedure
|
Valvular function
Time Frame: 30 days after procedure
|
Valvular function include valve stenosis, valve regurgitation, valve function (such as opening area, pressure gradient), perivalvular leakage, etc.
|
30 days after procedure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
December 13, 2019
Primary Completion (ACTUAL)
October 16, 2020
Study Completion (ACTUAL)
October 16, 2020
Study Registration Dates
First Submitted
January 29, 2021
First Submitted That Met QC Criteria
February 3, 2021
First Posted (ACTUAL)
February 9, 2021
Study Record Updates
Last Update Posted (ACTUAL)
February 21, 2021
Last Update Submitted That Met QC Criteria
February 18, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CSP12001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Stenosis
-
Hospices Civils de LyonRecruiting
-
Abbott Medical DevicesActive, not recruitingSevere Aortic Stenosis | Symptomatic Degenerative Aortic StenosisSpain, Italy, United Kingdom, Germany, Switzerland, Czechia, Australia, Belgium, Poland
-
Edwards LifesciencesActive, not recruitingAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Anteris Technologies Ltd.Active, not recruitingAortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisGeorgia
-
Anteris Technologies Ltd.Active, not recruitingAortic Stenosis | Aortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisUnited States
-
Edwards LifesciencesCompletedAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Ningbo Jenscare Biotechnology Co., Ltd.UnknownAortic Regurgitation | Severe Aortic Stenosis
-
Genesis Medtech CorporationRecruitingDiseases of Aortic Valve | Aortic Stenosis DiseaseChina
-
Saint Petersburg State University, RussiaNot yet recruitingIschemic Heart Disease | Mitral Insufficiency | Aortic Stenosis, Severe | Mitral Stenosis | Aortic Insufficiency | Ascending Aortic Aneurysm | Mitral Stenosis With Insufficiency | Tricuspid InsufficiencyRussian Federation
-
Pan XiangbinRecruiting
Clinical Trials on The experimental apparatus consisted of artificial aortic valve, transporter and grip-loading system.
-
Corcym S.r.lCompletedHeart Valve DiseasesNetherlands, Belgium, Germany, Austria, France, Italy, Portugal, Switzerland